$11.12
-0.08 (-0.71%)
USD · as of 2026-08-18 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where ABCL is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
2 interventional
Held by 10 tracked-famous managers (TWO SIGMA INVESTMENTS, LP, MARSHALL WACE, LLP, CITADEL ADVISORS LLC, RENAISSANCE TECHNOLOGIES LLC, MILLENNIUM MANAGEMENT LLC, +5 more) · FINRA short interest 9.7 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| A First-in-Human Phase 1 Single-Ascending Dose Study of ABCL575 in Healthy ParticipantsNCT07108894Incidence, frequency, and severity of adverse events (AEs)Randomized · Triple-masked · Treatment | Phase 1 | Active, not recruiting | Biological: ABCL575, Placebo (Normal Saline 0.9%) | Healthy Volunteers | 40 | Apr 2027 | ≤ 254 d | 2026-06-16 |
| Study Evaluating ABCL635 for Vasomotor Symptoms of MenopauseNCT07118891Frequency and severity of adverse events (AE)Randomized · Triple-masked · Treatment | Phase 1/2 | Active, not recruiting | Biological: ABCL635, Placebo | Vasomotor Symptoms Associated With Menopause, Healthy Volunteers | 136 | Feb 2027 | ≤ 193 d | 2026-06-15 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19